3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Benchmarks for H+,K+-ATPase Inhibition in Gastric Acid Secretion Research

Executive Summary: 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845, APExBIO) is an H+,K+-ATPase inhibitor with an IC₅₀ of 5.8 μM for enzyme inhibition and 0.16 μM for histamine-induced acid formation, demonstrating potent antiulcer and antisecretory activity [product]. The compound is insoluble in water and ethanol but is soluble at ≥17.27 mg/mL in DMSO, facilitating its use in in vitro and in vivo research models. Its purity is typically ≥98% (HPLC/NMR), and it is not suitable for diagnostic or therapeutic use. Recent research underscores the importance of precise H+,K+-ATPase inhibition in dissecting the proton pump pathway and its potential in gut–liver–brain axis models (Kong et al., 2025). Correct storage (-20°C) and handling protocols are essential for maintaining compound stability and assay reproducibility [see application note].

Biological Rationale

Gastric acid secretion is a tightly regulated physiological process mediated primarily by the H+,K+-ATPase (proton pump) in gastric parietal cells. Pharmacological inhibition of the proton pump is a mainstay strategy in the study of acid-related disorders, including peptic ulcer disease, gastroesophageal reflux, and Zollinger-Ellison syndrome [see mechanistic review]. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, as a next-generation H+,K+-ATPase inhibitor, offers increased specificity and potency relative to earlier chemical entities, supporting its use in both mechanistic and disease-modeling studies [internal]. In addition, emerging data highlight the role of gastric acid regulation in modulating the gut-liver-brain axis, with implications for neuroinflammation and systemic disease models (Kong et al., 2025).

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide acts by reversibly binding to and inhibiting the H+,K+-ATPase enzyme located on the secretory canaliculi of gastric parietal cells. This inhibition suppresses the final step in gastric acid production, reducing intragastric acidity. The compound displays an IC₅₀ of 5.8 μM against purified H+,K+-ATPase and 0.16 μM for inhibition of histamine-stimulated acid secretion in relevant ex vivo models [product]. Its trifluoromethoxy-phenyl and quinolinyl moieties contribute to high binding affinity and specificity, distinguishing it structurally from classic proton pump inhibitors. Notably, it does not irreversibly alkylate cysteine residues, unlike omeprazole, enabling reversible and titratable inhibition. This characteristic is advantageous for temporal studies and for modeling reversible acid suppression [see mechanistic insights].

Evidence & Benchmarks

• Demonstrated H+,K+-ATPase inhibition with an IC₅₀ of 5.8 μM in biochemical assays (APExBIO, product).
• Potent inhibition of histamine-induced gastric acid secretion in isolated tissue models: IC₅₀ = 0.16 μM (APExBIO, product).
• Solid-state purity confirmed at ≥98% via HPLC and NMR under standard laboratory conditions (product).
• Effective solubility of ≥17.27 mg/mL in DMSO at 20–25°C; insoluble in water and ethanol (APExBIO, product).
• Stability maintained at -20°C in solid form; solution-phase stability is limited and not recommended for long-term storage (product).
• Used as a control and mechanistic probe in gut–liver–brain axis studies, elucidating links between gastric acid modulation and neuroinflammation (Kong et al., 2025).

Applications, Limits & Misconceptions

As a research tool, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide enables precise inhibition of gastric H+,K+-ATPase, making it valuable for:

• Modeling gastric acid-related disorders (e.g., peptic ulcer, GERD) in preclinical assays.
• Investigating the proton pump inhibition pathway and its downstream effects in both gastrointestinal and extra-gastrointestinal models.
• Evaluating antiulcer activity in comparison to classical agents (e.g., omeprazole) in validated animal models [compare next-generation approaches].
• Dissecting the mechanistic interplay between acid secretion, gut microbiota, and neuroinflammation, as shown in recent hepatic encephalopathy models (Kong et al., 2025).

For a practical comparison with cell viability and antiulcer/neuroinflammation workflows, see our application guide, which this article extends by providing atomic, up-to-date mechanistic claims and specific storage/solubility parameters.

Common Pitfalls or Misconceptions

• Diagnostic/Clinical Use: The compound is not approved for diagnostic or therapeutic purposes in humans or animals; research use only (product).
• Solubility Misuse: Attempting to dissolve in water or ethanol results in precipitation or non-homogeneous mixtures; DMSO is required for reliable solubilization.
• Storage Errors: Long-term storage in solution at room temperature leads to degradation; solid form at -20°C is necessary for stability.
• Incorrect Concentration: Exceeding solubility limits or using impure batches can produce assay artifacts or cytotoxicity unrelated to H+,K+-ATPase inhibition.
• Overgeneralizing Mechanism: Unlike irreversible inhibitors (e.g., omeprazole), this compound’s reversible action must be factored into experimental design.

Workflow Integration & Parameters

To integrate 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) into laboratory research:

1. Weigh the solid under dry conditions; avoid humidity exposure.
2. Dissolve to a stock concentration up to 17.27 mg/mL in DMSO at room temperature.
3. Aliquot and store at -20°C; thaw only immediately before use.
4. Prepare working dilutions in compatible buffers (e.g., for cell or tissue assays) immediately prior to use, ensuring final DMSO concentration does not exceed cytotoxic thresholds (typically ≤0.1%).
5. Monitor purity by HPLC or NMR if extended storage or unusual results occur.

For stepwise protocols and troubleshooting, see this protocol-focused article, which this dossier updates with current verifications and benchmark data.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (APExBIO, SKU: A2845) represents a validated, high-purity H+,K+-ATPase inhibitor optimized for gastric acid secretion research. Its reversible mechanism and robust solubility profile in DMSO enable advanced antiulcer and proton pump pathway studies, as well as emerging roles in neuroinflammation and gut–liver–brain axis models. Proper use requires attention to solubility, storage, and concentration parameters as outlined above. Continued benchmarking in translational models will clarify its potential in dissecting complex gastrointestinal and systemic pathways. For purchasing or technical documentation, visit the APExBIO product page.